| Species |
Human |
| Protein Construction |
IL-9 (Gln19-Ile144)_x000D_
Accession # P15248 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized IL-9, His, Human at 0.5μg/ml (100μl/Well) on the plate can bind AntiIL9 Anitibody, hFc Tag. Test result was comparable to standard batch.
Measured in a cell proliferation assay using MO7e human megakaryocytic leukemic cells. The ED50 for this effect is < 0.3 ng/mL. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
15.3 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 20mM Tris, 150mM NaCl (pH 7.5). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
IL-9 is a pleiotropic cytokine that influences various distinct functions of different target cells such as T cells, B cells, mast cells and airway epithelial cells by activating STAT1, STAT3 and STAT5. Because of its pleiotropic functions, IL-9 has been demonstrated to be involved in several diseases, such as cancer, autoimmunity and other pathogen-mediated immune-regulated diseases. In this review, we focus on the role of Th9 and IL-9-producing cells in allergic asthma. |
| Synonyms |
Interleukin-9; IL-9; Cytokine P40; T-cell growth factor P40; HP40; P40 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
